藥物組合突破：Paxalisib，Pembrolizumab和化學療法在乳腺癌臨床試驗中表現出希望

1B期試驗的早期結果表明，藥物組合可顯著降低轉移性三陰性乳腺癌中循環的腫瘤細胞，從而提供新的希望。

Drug Combo Breakthrough: Paxalisib, Pembrolizumab, and Chemo Show Promise in Breast Cancer Clinical Trial

藥物組合突破：Paxalisib，Pembrolizumab和化學療法在乳腺癌臨床試驗中表現出希望

The landscape of breast cancer treatment is constantly evolving, and recent news from a Phase 1b clinical trial is generating excitement. This trial explores a novel drug combination—Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy—for metastatic triple-negative breast cancer.

乳腺癌治療的景觀在不斷發展，而1B期臨床試驗的最新消息正在引起興奮。該試驗探討了一種新型藥物組合 - 帕氏菌，pembrolizumab（KeyTruda®）和標準化療 - 用於轉移性三陰性乳腺癌。

Early Optimism: A Glimpse of Hope

早期樂觀：希望

Kazia Therapeutics announced encouraging preliminary results from the first patient in their Phase 1b trial. The 61-year-old woman with metastatic triple-negative breast cancer experienced a greater than 50% reduction in circulating tumor cells (CTCs) and a notable decrease in CTC clusters after just one cycle (21 days) of the investigational regimen.

Kazia Therapeutics在其1B期試驗中宣布了第一位患者的初步結果。這位61歲的患有三陰性乳腺癌的婦女的循環腫瘤細胞（CTC）降低了50％以上，並且在研究方案的一（21天）之後，CTC簇的CTC簇降低了顯著降低。

Why This Matters: Targeting Metastasis

為什麼這很重要：針對轉移

CTC clusters are known to be significant drivers of metastasis, resisting apoptosis, evading immune detection, and efficiently seeding new tumor sites. Standard chemotherapy can sometimes transiently increase CTCs, while immunotherapy alone may have delayed or modest effects. The rapid reduction in both CTC numbers and clusters with this drug combo is a potentially significant improvement.

眾所周知，CTC簇是轉移的重要驅動因素，可抵抗凋亡，逃避免疫檢測並有效地播種新的腫瘤部位。標準化療有時會瞬時增加CTC，而僅免疫療法可能會延遲或適度的影響。通過這種藥物組合，CTC數量和簇的快速減少是一種潛在的顯著改善。

The Science Behind the Success

成功背後的科學

These early clinical data mirror preclinical findings published in Molecular Cancer Therapeutics, highlighting Paxalisib's ability to disrupt both single CTCs and multicellular clusters when combined with immunotherapy. This reflects a synergistic effect, potentially offering a more effective early intervention against systemic disease progression.

這些早期的臨床數據鏡面臨床前發現在分子癌治療劑中發表，強調了帕薩西比（Paxalisib）與免疫療法結合使用時破壞單個CTC和多細胞簇的能力。這反映了一種協同作用，有可能提供更有效的早期干預，以防止全身性疾病進展。

Looking Ahead: What's Next for the Clinical Trial?

展望未來：臨床試驗的下一步是什麼？

Kazia Therapeutics is moving forward with several key steps:

Kazia Therapeutics正在採取多個關鍵步驟前進：

• Exploring the relationship between CTC kinetics and radiographic responses.
• Continuing enrollment in the Phase 1b study to assess safety, tolerability, and pharmacodynamics.
• Conducting a comprehensive analysis of the immune microenvironment and CTC kinetics across all patients.
• Monitoring long-term outcomes, including imaging, progression-free survival, and correlation with molecular biomarkers.

A New York State of Mind: Cautious Optimism

紐約的心態：謹慎的樂觀

While it's only one patient, the early results are undeniably exciting. Dr. John Friend, CEO of Kazia Therapeutics, expressed strong optimism, emphasizing the potential of this combination to offer a meaningful early intervention against systemic disease progression. Of course, more data is needed to confirm these initial findings and determine the long-term efficacy and safety of this drug combo. But for now, it's a reason to feel a little bit brighter about the future of breast cancer treatment.

雖然只有一名患者，但早期的結果無可否認是令人興奮的。 Kazia Therapeutics首席執行官John Friend博士表達了強烈的樂觀情緒，強調了這種組合的潛力，即提供有意義的早期干預，以防止全身性疾病進展。當然，需要更多數據來確認這些初始發現並確定該藥物組合的長期功效和安全性。但是目前，這是一個讓乳腺癌治療的未來更明亮的原因。